Cellectis Book/Share
What is the Book/Share of Cellectis?
The Book/Share of Cellectis is 4.36
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to Cellectis
What does Cellectis do?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Companies with book/share similar to Cellectis
- Morses Club PLC has Book/Share of 4.35
- Nokian Renkaat Oyj has Book/Share of 4.36
- Tandy Leather Factory has Book/Share of 4.36
- Metalla Royalty & Streaming has Book/Share of 4.36
- Las Vegas Sands Corp has Book/Share of 4.36
- WPP Plc has Book/Share of 4.36
- Cellectis has Book/Share of 4.36
- Jacques Bogart SA has Book/Share of 4.36
- Bowl America has Book/Share of 4.36
- Insignia Systems has Book/Share of 4.36
- Crown Crafts has Book/Share of 4.36
- Co-Diagnostics has Book/Share of 4.37
- ASE Technology Co.Ltd has Book/Share of 4.37